Suppr超能文献

非ST段抬高型心肌梗死患者血管造影的时机与预后:来自中国急性胸痛患者评估与管理注册研究的见解

Timing of angiography and outcomes in patients with non-ST-segment elevation myocardial infarction: Insights from the evaluation and management of patients with acute chest pain in China registry.

作者信息

Han Yu, Sun Shukun, Qiao Bao, Liu Han, Zhang Chuanxin, Wang Bailu, Wei Shujian, Chen Yuguo

机构信息

Department of Emergency and Chest Pain Center, Qilu Hospital of Shandong University, Jinan, China.

Clinical Research Center for Emergency and Critical Care Medicine of Shandong Province, Qilu Hospital of Shandong University, Jinan, China.

出版信息

Front Cardiovasc Med. 2022 Oct 20;9:1000554. doi: 10.3389/fcvm.2022.1000554. eCollection 2022.

Abstract

OBJECTIVE

Although an invasive strategy has been recommended within 24 h for patients with non-ST-segment elevation myocardial infarction (NSTEMI), the optimal timing of the invasive strategy remains controversial. We sought to investigate the association between the different timings of invasive strategies and clinical outcomes in patients with NSTEMI.

MATERIALS AND METHODS

Patients admitted with NSTEMI from the Evaluation and Management of Patients with Acute ChesT pain in China (EMPACT) registry between January 2016 and September 2017 were included. The primary outcomes were major adverse cardiac events (MACEs) within 30 days. Multivariable logistic regression was performed to assess independent risk factors for MACEs.

RESULTS

A total of 969 patients with NSTEMI from the EMPACT Registry were eligible for this study. Coronary angiography (CAG) was performed in 501 patients [<24 h, = 150 (15.5%); ≥ 24 h, = 351 (36.2%)]. The rate of MACEs at 30 days in all patients was 9.2%, including 54 (5.6%) deaths. Patients who underwent CAG had a lower rate of MACEs and mortality than those who did not receive CAG (MACEs: 5.6% vs. 13.0%, < 0.001; mortality: 1.6% vs. 9.8%, < 0.001). Nonetheless, no statistically significant difference was found in the rates of MACEs and mortality between the early (< 24 h) and delayed (≥ 24 h) CAG groups. Older age (OR: 1.036, 95% CI: 1.007, 1.065, = 0.014), and acute heart failure (OR: 2.431, 95% CI: 1.244, 4.749, = 0.009) increased the risk of MACEs and protective factors were underwent CAG (OR: 0.427, 95% CI: 0.219, 0.832, = 0.012) or PCI (OR: 0.376, 95% CI: 0.163, 0.868, = 0.022). In the multilevel logistic regression, older age (OR: 0.944, 95% CI: 0.932, 0.957, < 0.001), cardiogenic shock (OR: 0.233, 95% CI: 0.079, 0.629, = 0.009), pulmonary moist rales (OR: 0.368, 95% CI: 0.197, 0.686, = 0.002), and prior chronic kidney disease (OR: 0.070, 95% CI: 0.018, 0.273, < 0.001) was negatively associated with CAG.

CONCLUSION

This real-world cohort study of NSTEMI patients confirmed that the early invasive strategy did not reduce the incidence of MACEs and mortality within 30 days compared with the delayed invasive strategy in NSTEMI patients.

摘要

目的

尽管对于非ST段抬高型心肌梗死(NSTEMI)患者推荐在24小时内采取侵入性策略,但侵入性策略的最佳时机仍存在争议。我们试图研究NSTEMI患者不同侵入性策略时机与临床结局之间的关联。

材料与方法

纳入2016年1月至2017年9月在中国急性胸痛患者评估与管理(EMPACT)登记处收治的NSTEMI患者。主要结局是30天内的主要不良心脏事件(MACE)。进行多变量逻辑回归以评估MACE的独立危险因素。

结果

EMPACT登记处共有969例NSTEMI患者符合本研究条件。501例患者进行了冠状动脉造影(CAG)[<24小时,n = 150(15.5%);≥24小时,n = 351(36.2%)]。所有患者30天的MACE发生率为9.2%,包括54例(5.6%)死亡。接受CAG的患者MACE和死亡率低于未接受CAG的患者(MACE:5.6%对13.0%,P<0.001;死亡率:1.6%对9.8%,P<0.001)。然而,早期(<24小时)和延迟(≥24小时)CAG组之间的MACE和死亡率未发现统计学上的显著差异。年龄较大(OR:1.036,95%CI:1.007,1.065,P = 0.014)和急性心力衰竭(OR:2.431,95%CI:1.244,4.749,P = 0.009)增加了MACE的风险,保护因素是接受CAG(OR:0.427,95%CI:0.219,0.832,P = 0.012)或PCI(OR:0.376,95%CI:0.163,0.868,P = 0.022)。在多水平逻辑回归中,年龄较大(OR:0.944,95%CI:0.932,0.957,P<0.001)、心源性休克(OR:0.233,95%CI:0.079,0.629,P = 0.009)、肺部湿啰音(OR:0.368,95%CI:0.197,0.686,P = 0.002)和既往慢性肾脏病(OR:0.070,95%CI:0.018,0.273,P<0.001)与CAG呈负相关。

结论

这项针对NSTEMI患者的真实世界队列研究证实,与延迟侵入性策略相比,早期侵入性策略并未降低NSTEMI患者30天内MACE的发生率和死亡率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7962/9630349/79d4acbfdd30/fcvm-09-1000554-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验